ABBVQ2 FY20261/5Estimate vs Actual
Earnings per Share
- Estimate
- $3.68
- Actual
- $3.65
−0.7% vs Estimate
Revenue
- Estimate
- $17.1 B
- Actual
- $17.0 B
−0.6% vs Estimate
AbbVie Inc Q2 FY2026 · Story
Read the quarter card by card, ready to share.
ABBVQ2 FY20261/5ABBVQ2 FY20262/5Guidance
Full-Year Adjusted EPS
- Company Guidance
- 13.87 – 14.07 $
- Market Estimate
- 14.08 $
Midpoint 0.8% Below Estimate ▼
Full-Year Revenue
- Company Guidance
- 67.6 billion
Raised 0.4% ▲
Skyrizi Full-Year Sales
- Company Guidance
- 21.7 billion
Raised 0.5% ▲
ABBVQ2 FY20263/5Price Reaction
First Full Session
− 2.5%
From the prior close to the report-day close.
ABBVQ2 FY20264/5In 30 Seconds
Revenue rose 10.2% year over year to $16.99B, and adjusted EPS climbed 22.9% to $3.65.
- Skyrizi and Rinvoq together sold $8.03B and made up 47% of total revenue on their own.
- The stock fell 2.5% on earnings day after Apogee dilution trimmed full-year earnings guidance by 4 cents.
First point of the analysis's “In 30 Seconds”.
Full AnalysisABBVQ2 FY20265/5Score
74/ 100
ViewBUY
Not Investment Advice